Standard Operating Procedure for Review of Product Information Updates From Safety Data
| Department | Regulatory Affairs |
| SOP No. | RA/2026/754 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 16/04/2026 |
| Effective Date | 16/04/2026 |
| Review Date | 16/04/2028 |
Purpose
This SOP establishes a standardized procedure for the systematic review, evaluation, and updating of product information derived from safety data. It ensures that all safety-related updates are accurately assessed and reflected in the product labelling, artwork, and related documentation to maintain compliance with regulatory requirements and to safeguard patient health.
Scope
This SOP applies to all processes and personnel involved in reviewing safety data reports, pharmacovigilance inputs, and other relevant safety sources for the purpose of updating product information. It covers all pharmaceutical dosage forms, packaging materials, labelling, and artwork controlled by the Regulatory Affairs department. Activities excluded from this SOP are those unrelated to safety data impacts on product information, such as quality control testing and manufacturing batch release.
Responsibilities
- Pharmacovigilance Team: Identify and provide safety data related to adverse events or updated safety information.
- Regulatory Affairs Team: Review safety data, assess the impact on product information, coordinate with relevant stakeholders, and implement required updates.
- Quality Assurance: Review and approve changes to ensure compliance with regulatory and quality standards.
- Documentation Control: Manage revision, version control, and archiving of updated documents and labelling materials.
- Medical Affairs (if applicable): Provide clinical assessment support for safety data interpretation.
Accountability
The Head of Regulatory Affairs is accountable for ensuring effective implementation, ongoing compliance, periodic review, and escalation of issues related to the review and update of product information from safety data. The Head of Quality Assurance is accountable for ensuring that changes are in line with quality systems and regulatory compliance requirements.
Procedure
1. Receipt of Safety Data: Pharmacovigilance team receives safety data, including adverse event reports, signal detection alerts, periodic safety update reports (PSURs), and health authority communications related to product safety.
2. Data Evaluation and Initial Review: Regulatory Affairs promptly reviews the safety data to determine potential impacts on product information, such as labelling, packaging, or artwork. Collaboration with Medical Affairs or subject matter experts may be sought for clinical interpretation.
3. Impact Assessment: Regulatory Affairs conducts a detailed impact assessment, identifying sections of product information requiring updates (e.g., warnings, contraindications, dosage adjustments). Risk assessments should be documented.
4. Preparation of Updated Documentation: Draft revised product information documents including labelling text and artwork amendments while ensuring alignment with regulatory guidances and template standards.
5. Internal Review and Approval: Circulate the draft updates to Quality Assurance and other relevant departments for review. Address any queries or concerns raised during the review phase and obtain formal approvals.
6. Regulatory Submission (if applicable): Submit updated product information to health authorities as per region-specific regulatory requirements, maintaining communication on submission status and responses.
7. Document Control and Implementation: Upon approval, Documentation Control updates controlled versions of documents, manages version numbering, and ensures archival of superseded versions. Updated labelling and artwork are released for use across all relevant distribution channels and manufacturing sites.
8. Training and Communication: Regulatory Affairs ensures that relevant internal stakeholders are informed and trained on updated product information to avoid misinterpretation or errors.
9. Record Keeping: Maintain comprehensive records of the review process, impact assessments, approvals, communications with authorities, training logs, and final updated documents in accordance with company policies and applicable regulations.
10. Monitoring and Review: Periodically review the effectiveness of this SOP and the timeliness and accuracy of safety data-driven updates during management reviews. Escalate and address any deviations or non-conformities appropriately.
Abbreviations
- PSUR: Periodic Safety Update Report
- GMP: Good Manufacturing Practice
- QA: Quality Assurance
- RA: Regulatory Affairs
- PvP: Pharmacovigilance
- SOP: Standard Operating Procedure
Documents
The following documents are essential for effective execution and control under this SOP:
- Safety Data Impact Assessment Report (Annexure-1)
- Product Information Change Request Form (Annexure-2)
- Regulatory Submission Tracking Log (Annexure-3)
References
- ICH E2C (Pharmacovigilance Planning) Guidelines
- EU GMP Annex 16 – Certification by the Qualified Person and Batch Release
- FDA Guidance for Industry on Safety Reporting Requirements
- ICH Q7 – Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
- Company Quality Management System Documentation
- Applicable regional regulatory labeling and pharmacovigilance requirements
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Safety Data Impact Assessment Report
Purpose: To document evaluation of safety data and determine necessary updates to product information.
| Report ID | SDAR-2026-001 |
| Assessment Date | 10/04/2026 |
| Safety Data Source | PSUR Q1 2026 |
| Product Name | ExamplePharma Drug X |
| Safety Concern Summary | New adverse reaction detected – increased frequency of dizziness |
| Impact on Labelling | Update Warnings and Precautions section |
| Risk Level | Moderate |
| Assessment Performed By | Regulatory Affairs Team |
| Comments | Recommend urgent update to health authorities |
Annexure-2: Product Information Change Request Form
Purpose: To formally request updates to product information based on safety data review findings.
| Change Request No. | PI-CR-2026-015 |
| Date | 12/04/2026 |
| Product Name | ExamplePharma Drug X |
| Description of Change | Add dizziness warning and update precautionary statements in labelling |
| Requested By | Regulatory Affairs |
| Priority | High |
| Status | Pending Approval |
| Approvals | Quality Assurance: Pending Medical Affairs: Approved |
Annexure-3: Regulatory Submission Tracking Log
Purpose: To track submissions of updated product information to regulatory authorities and their status.
| Submission ID | Date Submitted | Regulatory Body | Product Name | Submission Type | Status | Next Action Date |
|---|---|---|---|---|---|---|
| SUB-RA-2026-034 | 14/04/2026 | FDA | ExamplePharma Drug X | Labelling Update | Under Review | 30/04/2026 |
| SUB-RA-2026-035 | 15/04/2026 | EMA | ExamplePharma Drug X | Labelling Update | Accepted | N/A |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 16/04/2026 | 1.0 | Initial issue | New SOP creation |